MolPharm xPharm- The Comprehensive Pharmacology Reference

Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Castle, N. A.
Right arrow Articles by Sabatier, J.-M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Castle, N. A.
Right arrow Articles by Sabatier, J.-M.

Vol. 63, Issue 2, 409-418, February 2003

Maurotoxin: A Potent Inhibitor of Intermediate Conductance Ca2+-Activated Potassium Channels

N. A. Castle, D. O. London, C. Creech, Z. Fajloun, J. W. Stocker, and J.-M. Sabatier

Icagen Inc., Durham, North Carolina (N.A.C., D.O.L., C.C., J.W.S.); and Centre National de la Recherche Scientifique, Unité Mixte Recherche 6560, l'Institut Fédératif de Recherches Jean Roche, Marseille, France (Z.F., J.-M.S.)

Maurotoxin, a 34-amino acid toxin from Scorpio maurus scorpion venom, was examined for its ability to inhibit cloned human SK (SK1, SK2, and SK3), IK1, and Slo1 calcium-activated potassium (KCa) channels. Maurotoxin was found to produce a potent inhibition of Ca2+-activated 86Rb efflux (IC50, 1.4 nM) and inwardly rectifying potassium currents (IC50, 1 nM) in CHO cells stably expressing IK1. In contrast, maurotoxin produced no inhibition of SK1, SK2, and SK3 small-conductance or Slo1 large-conductance KCa channels at up to 1 µM in physiologically relevant ionic strength buffers. Maurotoxin did inhibit 86Rb efflux (IC50, 45 nM) through, and 125I-apamin binding (Ki, 10 nM) to SK channels in low ionic strength buffers (i.e., 18 mM sodium, 250 mM sucrose), which is consistent with previous reports of inhibition of apamin binding to brain synaptosomes. Under similar low ionic strength conditions, the potency for maurotoxin inhibition of IK1 increased by ~100-fold (IC50, 14 pM). In agreement with its ability to inhibit recombinant IK1 potassium channels, maurotoxin was found to potently inhibit the Gardos channel in human red blood cells and to inhibit the KCa in activated human T lymphocytes without affecting the voltage-gated potassium current encoded by Kv1.3. Maurotoxin also did not inhibit Kv1.1 potassium channels but potently blocked Kv1.2 (IC50, 0.1 nM). Mutation analysis indicates that similar amino acid residues contribute to the blocking activity of both IK1 and Kv1.2. The results from this study show that maurotoxin is a potent inhibitor of the IK1 subclass of KCa potassium channels and may serve as a useful tool for further defining the physiological role of this channel subtype.

Copyright © 2003 by The American Society for Pharmacology and Experimental Therapeutics


This article has been cited by other articles:


Home page
 J. Pharmacol. Exp. Ther.Home page
N. D. Sonawane, O. Zegarra-Moran, W. Namkung, L. J. V. Galietta, and A. S. Verkman
{alpha}-Aminoazaheterocyclic-Methylglyoxal Adducts Do Not Inhibit Cystic Fibrosis Transmembrane Conductance Regulator Chloride Channel Activity
J. Pharmacol. Exp. Ther., May 1, 2008; 325(2): 529 - 535.
[Abstract] [Full Text] [PDF]

Home page
 J. Gen. Physiol.Home page
J. Ledoux, A. D. Bonev, and M. T. Nelson
Ca2+-activated K+ Channels in Murine Endothelial Cells: Block by Intracellular Calcium and Magnesium
J. Gen. Physiol., January 28, 2008; 131(2): 125 - 135.
[Abstract] [Full Text] [PDF]

Home page
 Mol. Pharmacol.Home page
S. Mouhat, G. Teodorescu, D. Homerick, V. Visan, H. Wulff, Y. Wu, S. Grissmer, H. Darbon, M. De Waard, and J.-M. Sabatier
Pharmacological Profiling of Orthochirus scrobiculosus Toxin 1 Analogs with a Trimmed N-Terminal Domain
Mol. Pharmacol., January 1, 2006; 69(1): 354 - 362.
[Abstract] [Full Text] [PDF]

Home page
 J. Dent. Res.Home page
P. Valverde, T. Kawai, and M.A. Taubman
Potassium Channel-blockers as Therapeutic Agents to Interfere with Bone Resorption of Periodontal Disease
J. Dent. Res., June 1, 2005; 84(6): 488 - 499.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
I. Regaya, C. Beeton, G. Ferrat, N. Andreotti, H. Darbon, M. De Waard, and J.-M. Sabatier
Evidence for Domain-specific Recognition of SK and Kv Channels by MTX and HsTx1 Scorpion Toxins
J. Biol. Chem., December 31, 2004; 279(53): 55690 - 55696.
[Abstract] [Full Text] [PDF]

Home page
 Mol. Pharmacol.Home page
V. Visan, Z. Fajloun, J.-M. Sabatier, and S. Grissmer
Mapping of Maurotoxin Binding Sites on hKv1.2, hKv1.3, and hIKCa1 Channels
Mol. Pharmacol., November 1, 2004; 66(5): 1103 - 1112.
[Abstract] [Full Text] [PDF]

Home page
 Biol. Reprod.Home page
A. I. Yudin, T. L. Tollner, M.-W. Li, C. A. Treece, J. W. Overstreet, and G. N. Cherr
ESP13.2, a Member of the {beta}-Defensin Family, Is a Macaque Sperm Surface-Coating Protein Involved in the Capacitation Process
Biol Reprod, October 1, 2003; 69(4): 1118 - 1128.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
S. M'Barek, I. Lopez-Gonzalez, N. Andreotti, E. di Luccio, V. Visan, S. Grissmer, S. Judge, M. El Ayeb, H. Darbon, H. Rochat, et al.
A Maurotoxin with Constrained Standard Disulfide Bridging: INNOVATIVE STRATEGY OF CHEMICAL SYNTHESIS, PHARMACOLOGY, AND DOCKING ON K+ CHANNELS
J. Biol. Chem., August 15, 2003; 278(33): 31095 - 31104.
[Abstract] [Full Text] [PDF]


Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
All ASPET Journals Molecular Pharmacology Pharmacological Reviews
Molecular Interventions Drug Metabolism and Disposition

Copyright © 2003 by the American Society for Pharmacology and Experimental Therapeutics